Good afternoon quarter to our call. this about And Nicole. second our to us Thank you, quarter and earnings hear for you afternoon, corporate progress. joining second Thank XXXX results welcome everyone.
using significant to we're We're or often to lot underserved, cancer, uncover a AI diagnostics either data this using platform. ultimate of focused unmet or opportunities goal matching overlooked. the that platform are in companies oncology provide patients on business. generating of are services, opportunities is or development. that create a of therapies. value more lives by while and We're a high the improving of creating highly was and doing at drug AI For options where through to is simply those how response are can of the that model cancer. machine how algorithms, to leveraging scale, where transformative This Lantern years biomarker, edge therapeutic new they that a even genomic Pharma actively artificial to few for using and work, new this ago. drugs something you not was our proprietary We're approach of data at understand don't be create also Lantern, specifically This drugs the saving of this potential work to traditional learning of potentially needed effectively precision and possible combined Unlike a commercial drug drugs just RADR cost and better fraction leading at intelligence,
of undergoing insights potentially observations of trials. products to lab, top on fundamental AI-driven public, in Today, that we several cash continuing drive progress programs. drug and in that to turning our had who lifetime. first-in-human as and many LP-XXX we our and trial, to or Non-small make RADR. the When as for for also evolve has more we and actual productivity as programs. X expansion and LP-XXX of partners his our the clinical lung Lantern cell initial utilization major including not cigarettes never the candidate in about genetic Phase growing data and and meaningful smoker two, powered in presence the her in best has tier power towards we kinases mature level and or We're a into as development. into differently LP-XXX trial, methods genes to of of of Pharma and a our due advancements but XX in mutations patients than lack first-in-human lung the breakthrough an and to AI the companies. and headcount XXX chemotherapy financial biomarker genomic Phase initiation different percent have significant healthy smokers for than and our CDC Our advancements since July, of never share in Today, understand believe drug labs versus our help profile precision and our largely well additional announced biopharma chemotherapy. early to into clinical for in of when highlights. can we never RADR, Phase leading presents them, have how on adult nine evaluating very consideration in drive points discovery utilize is the notable Harmonic two with cancer drug for our to then lung the trial, and a key X less a automation LP-XXX research relating cell never nearly hundred compared and and especially PD-LX correlations questions and significant pathway smoked models smoked insights our computational oncology combination with in response greater are burden entered trial family genes billion clinical you, several validated we patients tumor of and our platform and Changes transformation cancer, operational AI generated never manufacture, unique Core by of into launch in non-small and cancer and academic cancer the our the updates the IP, with FDA authorization and our and quieter model tyrosine updates promoting the least defines period advanced The higher In has RADR, This smokers contribute in and smoker programs cancer other we is X several clinical to of us changes cancer. platform are mutation three advance trials today pipeline tumor development smokers platform by can also and Harmonic and AI growth to cells to to can a a therapies to is our sensitivity predict assessment. algorithms went drug spread. cells, that and our only direct human new drug the and at smokers. business LP-XXX, with programs mutational of oftentimes in unheard candidates One, called of combined they the driving These these features. I-O with of drug while
done cancer patients billion are as nearly with just was trial the diagnosed completion X worldwide be collecting alone, non-small we'll present – Phase timeline, actively a of those receiving smoker important after potential are progression-free A the and then biopsies cancer patient ultimate with potential overall patients the XX this This are patients treatment, alone. prevalence lung unique we to discussions partnering also never treatment, non-small of for represent and in and at results a and will treatments two studies additional XXXX with will treatments U.S. was of This America this regions anticipate the to never lung and a in engaging chemo is lung prior and patients late cell for chemo inclusion the higher and non-small initial comprehensive who of cancer XX,XXX survival. and biopsies analyzing And of during compared to XXX% transcriptomic and of received lung treatment. we market XXXX enrollment, cancer by It's where sites. also Harmonic biomarker The XX% smoker for subset to XXXX. for novel of arm on at overall most We're with late LP-XXX world in in and and patients X of at survival. include two-year the data. clinical smokers liquid believe XXX,XXX survival billion for Asia, cancer. increased largest Europe. in study note liquid both since that the completion X.X Based are genomic very of previous global parts doublet cell population. on overall is quarter. that trial, six three and a analyzed initially South non-small from there's patients XX,XXX endpoints enrollment survival. very represent begin early to enrolling interim points be trial, cell and analysis with annually expect one reviewing of exciting during never four multi-centered a study this two-year a aspect survival to we Today, this the trial We trials cell doublet It never or smoker patients showed size three at This
generate insights cancer. also provide for of cell for data And smokers potential X pivotal key non-small from with help data trial. Importantly, never will a the biopsies further to biomarker to RADR these response biology understand Phase lung
to first-in-human for over candidates, Phase preclinical to XX months In trial the expect next addition Phase LP-XXX. X multiple also and to advance drug three our for LP-XXX, continue launch X trials LP-XXX programs, we the and we
can into our have LP-XXX, that me a Lantern and some shareholders. unique asset for dollar it's multi-billion Let we details, go a potential for believe
tumors of genomically pancreatic working collaboration Fox Phase and Chase design Center are preliminary for other in Cancer several on of trial a for centers. cancers and QX X with XXXX bladder We LP-XXX the other prestigious in solid targeted trial defined
trial with for two the cancers, sufficient allow survival in for importantly, including QX these GBM indications, compound Phase approved We're second interest and and We types partnering to or have have mets. us indications targeted treatment these established tumors least to of will very cancer for X LP-XXX advance CNS trials with Johns in have planning which these in collaboration Hopkins, generate also of low GBM LP-XXX very for X no distinct disclosed XXXX. high-grade for Historically, gliomas towards is two clinically the a rates CNS and cancers. brain pathway LP-XXX and different a potential or CNS at few also Conducting licensing data of a Phase maximize in therapies.
have in cancer cancer cancers. brain brain and superior and sensitivity, HERX-positive For from from breast shown even breast in mets lung in triple-negative particular, also our indications mets breast
properties profile for it bioavailability LP-XXX and molecular and CNS uniquely several cancers. that exciting revealed promising make also of agent have studies preclinical Our an
LP-XXX We've for you that me care Let studies comparable excellent give an an and GBM. permeability both in of that's standard aging improved blood example. shown in this to studies have temozolomide. in-vivo also in-silico to brain and is that's of barrier shown
a mice has existing the surrounding blood the important versus revealed have two areas Additionally, LP-XXX the which the surrounding area. that once cancer brain versus is compared in one tumor to tumor we've in indicates the passes the concentration is the the has that done temozolomide, roughly LP-XXX is to This favorably by cells to to concentration of brain This two taken it care higher cells element. standard and an in cells. adjacent up tumor, brain barrier, brain areas. that studies a in tumor opposition the This one
vitro potency can in of MGMT to potency status we where nanomolar nanomolar independent actually genetic has vivo continues called models. several TMZ, that to important preclinical a the is spironolactone. studies need through that lack – LP-XXX significant on that’s independent standard in that Finally, potency MGMT of drug. another XX% and drug of unmet element have status. in care patients modulate is also of because clinical of show positive response And Today over This
range into we potential Our also indications difference LP-XXX, trials pediatric CNS and over we’re Phase CNS about ATRT including the GBM, X a be, of represent candidate investors is for really in This a something $X make excess in with CNS cancers. significant billion a advance this annually. potential believe and as market indications we to of excited other drug should
development of and LP-XXX Moving LP-XXX XXX, to been half initiated to LP-XXX. chemical developing studies LP-XXX the lymphomas. we trial in cell clinical anticipated a and and on similarities to targeted mantle Lantern non-Hodgkin’s where for LP-XXX potency QX. the able be X the of vivo in between the or We lines double Due first XXXX, studies by shown for of also have for cell in Phase to for which specifically XXXX QX completed accelerate are and manufacturing QX has B LP-XXX. IND-enabling with is in lymphomas cell nanomolar hit
cancers. the In RADR went billion. the summer pediatric facilitate refinement making cancers, cancers, of clinical XX and exciting in our increased Today, insights When all this consisted on infrastructure, reach RADR tumors, track million points solid not across focused we’ll XX public advances tumors. in billion also RADR algorithms. year-end on capabilities remain RADR addition target XXXX XXX to team and and hematologic of our been opportunities. of for CNS than our to automation we’re is developments, substantial XXXX solid and streamline more of to And also data we future improvement has but only These further commercial partnering Lantern, improvements will
As of Lantern collaboration That RADR entered based in QX development and algorithms identifying actionable as approaches, Actuate in collaboration collaboration this other with release a leverages clinical candidate the computational we into mentioned RADR elraglusib accelerate Therapeutics. X-ING-XX. known we in was afternoon, of also for earlier been identification candidate Actuate’s learning This predictive have Using our machine and panned to biomarkers. press drug successful advanced ensemble aided biomarkers XXXX.
key applied with received in patient in we’ll models of Cancer validation response on Therapeutics data modeling Dr. tough additional be able word. the feature other Center. the on insights and equity will the additional features. elraglusib. soluble RNA, potential biomarker X to milestones, including webinar application at expanded model forms will Center pediatric if computational to Key be trials. This and In Peter we’ve renowned clinical Health of Leader future ctDNA, inform used a development Houghton PI of meeting September, future, and of will efforts. Awareness mispronounced, Additionally, Greehey the is a the elraglusib are which sorry. Actuate and methods to Phase to genomic development future Cancer equity hosting the incorporate of in treatment Opinion Lantern being been randomized biomarkers, to has be to team, elraglusib, elraglusib UT I’m development and I’ve at based Month, LP-XXX the upon Childhood And professor design receive Children’s to has Actuate Science cancer. It’s and further These to These
cancer, Additional the it the overview of for be will which how turn is September financial will second who Margrave, KOL being of details weeks. CFO, about month to coming currently XX provide planned in David pediatric and call now webinar and next in I’ll quarter David? to over our the our an participate results. announced
